¡Hola! Iniciá sesión
Inicio > Productos

Theragnostics, An Issue of PET Clinics

$134.982,00
10% de descuento pagando con Transferencia
Ver más detalles

FORMATO

Edicion

PAPEL

Edicion

EBOOK
Descripcion
Indice
Autores
Muestra
Ficha Técnica
Descripción

  • Contains 12 relevant, practice-oriented topics including theragnostics trials; neuroendocrine tumors: diagnostics; prostate-specific membrane antigen: diagnostics; theragnostics: post-therapy imaging; fibroblast-activation-protein inhibitors (FAPI) theragnostics; and more.
  • Provides in-depth clinical reviews on theragnostics, offering actionable insights for clinical practice.
  • Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
In this issue of PET Clinics, guest editors Drs. Andrei Iagaru and Heather A. Jacene bring their considerable expertise to the topic of Theragnostics. Top experts in the field discuss neuroendocrine tumors: beta-labeled peptides; prostate-specific membrane antigen: interpretation criteria, standardized reporting and the use of artificial intelligence; prostate cancer (gastrin-releasing peptide receptor); selective internal radiation therapy; future directions in theragnostics; and more.

1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. CME Accreditation Page - p. xi 8. Preface - p. xiii 9. Alpha and Beta Radiation for Theragnostics - p. 307 10. Neuroendocrine Tumors: Diagnostics - p. 325 11. Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors - p. 341 12. Prostate-specific Membrane Antigen: Diagnostics - p. 351 13. Prostate-specific Membrane Antigen: Interpretation Criteria, Standardized Reporting, and the Use of Machine Learning - p. 363 14. Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals - p. 371 15. Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals - p. 389 16. Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years - p. 401 17. Treatment Response Imaging in Prostate Cancer - p. 417 18. Hepatic Radioembolization: A Multistep Theragnostic Procedure - p. 431

Descripcion
Descripción

  • Contains 12 relevant, practice-oriented topics including theragnostics trials; neuroendocrine tumors: diagnostics; prostate-specific membrane antigen: diagnostics; theragnostics: post-therapy imaging; fibroblast-activation-protein inhibitors (FAPI) theragnostics; and more.
  • Provides in-depth clinical reviews on theragnostics, offering actionable insights for clinical practice.
  • Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
In this issue of PET Clinics, guest editors Drs. Andrei Iagaru and Heather A. Jacene bring their considerable expertise to the topic of Theragnostics. Top experts in the field discuss neuroendocrine tumors: beta-labeled peptides; prostate-specific membrane antigen: interpretation criteria, standardized reporting and the use of artificial intelligence; prostate cancer (gastrin-releasing peptide receptor); selective internal radiation therapy; future directions in theragnostics; and more.

1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. CME Accreditation Page - p. xi 8. Preface - p. xiii 9. Alpha and Beta Radiation for Theragnostics - p. 307 10. Neuroendocrine Tumors: Diagnostics - p. 325 11. Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors - p. 341 12. Prostate-specific Membrane Antigen: Diagnostics - p. 351 13. Prostate-specific Membrane Antigen: Interpretation Criteria, Standardized Reporting, and the Use of Machine Learning - p. 363 14. Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals - p. 371 15. Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals - p. 389 16. Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years - p. 401 17. Treatment Response Imaging in Prostate Cancer - p. 417 18. Hepatic Radioembolization: A Multistep Theragnostic Procedure - p. 431

Indice
Autores
Muestra
Ficha Técnica